Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease
Contemporary evidence supports device-based transcatheter interventions for the management of patients with structural heart disease. These procedures, which include aortic valve implantation, mitral or tricuspid valve repair/implantation, left atrial appendage occlusion, and patent foramen ovale closure, profoundly differ with respect to clinical indications and procedural aspects. Yet, patients undergoing transcatheter cardiac interventions require antithrombotic therapy before, during, or after the procedure to prevent thromboembolic events. However, these therapies are associated with an increased risk of bleeding complications. To date, challenges and controversies exist regarding balancing the risk of thrombotic and bleeding complications in these patients such that the optimal antithrombotic regimens to adopt in each specific procedure is still unclear. In this review, we summarize current evidence on antithrombotic therapies for device-based transcatheter interventions targeting structural heart disease and emphasize the importance of a tailored approach in these patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:144 |
|---|---|
| Enthalten in: |
Circulation - 144(2021), 16 vom: 19. Okt., Seite 1323-1343 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Calabrò, Paolo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulants |
|---|
| Anmerkungen: |
Date Completed 29.12.2021 Date Revised 29.12.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1161/CIRCULATIONAHA.121.054305 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332024709 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332024709 | ||
| 003 | DE-627 | ||
| 005 | 20231225214739.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/CIRCULATIONAHA.121.054305 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1106.xml |
| 035 | |a (DE-627)NLM332024709 | ||
| 035 | |a (NLM)34662163 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Calabrò, Paolo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.12.2021 | ||
| 500 | |a Date Revised 29.12.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Contemporary evidence supports device-based transcatheter interventions for the management of patients with structural heart disease. These procedures, which include aortic valve implantation, mitral or tricuspid valve repair/implantation, left atrial appendage occlusion, and patent foramen ovale closure, profoundly differ with respect to clinical indications and procedural aspects. Yet, patients undergoing transcatheter cardiac interventions require antithrombotic therapy before, during, or after the procedure to prevent thromboembolic events. However, these therapies are associated with an increased risk of bleeding complications. To date, challenges and controversies exist regarding balancing the risk of thrombotic and bleeding complications in these patients such that the optimal antithrombotic regimens to adopt in each specific procedure is still unclear. In this review, we summarize current evidence on antithrombotic therapies for device-based transcatheter interventions targeting structural heart disease and emphasize the importance of a tailored approach in these patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a anticoagulants | |
| 650 | 4 | |a atrial appendage | |
| 650 | 4 | |a atrial fibrillation | |
| 650 | 4 | |a foramen ovale, patent | |
| 650 | 4 | |a mitral valve | |
| 650 | 4 | |a thrombosis | |
| 650 | 4 | |a transcatheter aortic valve replacement | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 700 | 1 | |a Gragnano, Felice |e verfasserin |4 aut | |
| 700 | 1 | |a Niccoli, Giampaolo |e verfasserin |4 aut | |
| 700 | 1 | |a Marcucci, Rossella |e verfasserin |4 aut | |
| 700 | 1 | |a Zimarino, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Spaccarotella, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Renda, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Patti, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Andò, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Moscarella, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Mancone, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Cesaro, Arturo |e verfasserin |4 aut | |
| 700 | 1 | |a Giustino, Gennaro |e verfasserin |4 aut | |
| 700 | 1 | |a De Caterina, Raffaele |e verfasserin |4 aut | |
| 700 | 1 | |a Mehran, Roxana |e verfasserin |4 aut | |
| 700 | 1 | |a Capodanno, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Valgimigli, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Windecker, Stephan |e verfasserin |4 aut | |
| 700 | 1 | |a Dangas, George D |e verfasserin |4 aut | |
| 700 | 1 | |a Indolfi, Ciro |e verfasserin |4 aut | |
| 700 | 1 | |a Angiolillo, Dominick J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Circulation |d 1950 |g 144(2021), 16 vom: 19. Okt., Seite 1323-1343 |w (DE-627)NLM000039020 |x 1524-4539 |7 nnns |
| 773 | 1 | 8 | |g volume:144 |g year:2021 |g number:16 |g day:19 |g month:10 |g pages:1323-1343 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1161/CIRCULATIONAHA.121.054305 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 144 |j 2021 |e 16 |b 19 |c 10 |h 1323-1343 | ||